The company
Rhythm Pharmaceuticals, Inc.
RYTM · Nasdaq
RYTM stood above a rising 150-day average in 24 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 11.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $75.7M
- Officials’ trades on record
- 1
- Institutions holding
- 288 (+19)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 24 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
1 disclosed lines: House 0, Senate 0, executive 1; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy | sold | $50k–$100k | 10 Jun 2021filed 8 Sep 2021 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| David P. MeekerPresident and CEO | sold | 6,439at $101.75 | 14 Sep 2026filed 14 Sep 2026 |
| David P. MeekerPresident and CEO | sold | 30,746at $102.35 | 14 Sep 2026filed 14 Sep 2026 |
| David P. MeekerPresident and CEO | sold | 8,698at $103.43 | 14 Sep 2026filed 14 Sep 2026 |
| David P. MeekerPresident and CEO | sold | 1,817at $104.55 | 14 Sep 2026filed 14 Sep 2026 |
| David P. MeekerPresident and CEO | sold | 2,300at $105.19 | 14 Sep 2026filed 14 Sep 2026 |
| Hunter C. SmithChief Financial Officer | sold | 23,072at $104.59 | 31 Aug 2026filed 1 Sep 2026 |
| Hunter C. SmithChief Financial Officer | sold | 11,514at $105.37 | 31 Aug 2026filed 1 Sep 2026 |
| Hunter C. SmithChief Financial Officer | sold | 28,188at $106.20 | 31 Aug 2026filed 1 Sep 2026 |
| Jennifer Kayden LeeEVP, Head of North America | sold | 75,834at $117.38 | 13 Aug 2026filed 14 Aug 2026 |
| Alastair GarfieldChief Scientific Officer | sold | 2,007at $116.11 | 13 Aug 2026filed 17 Aug 2026 |
| Alastair GarfieldChief Scientific Officer | sold | 1,556at $117.08 | 13 Aug 2026filed 17 Aug 2026 |
| Alastair GarfieldChief Scientific Officer | sold | 3,400at $118.28 | 13 Aug 2026filed 17 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 6,666,837$740.2M | 00.0% |
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 6,156,902$683.6M | -80,249−1.3% |
| BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026 | 5,604,483$622.3M | 00.0% |
| PRIMECAP MANAGEMENT COreduced · filed 14 Aug 2026 | 3,168,853$351.8M | -248,656−7.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 3,136,895$348.3M | +96,177+3.2% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 3,005,977$333.8M | +38,152+1.3% |
| JPMORGAN CHASE & COnew · filed 12 Aug 2026 | 2,652,746$292.2M | +2,652,746 |
| PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026 | 2,586,295$287.2M | +212,500+9.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 2,573,529$285.7M | +301,678+13.3% |
| WESTFIELD CAPITAL MANAGEMENT CO LPadded · filed 12 Aug 2026 | 2,208,595$245.2M | +279,472+14.5% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.